全文获取类型
收费全文 | 340969篇 |
免费 | 15755篇 |
国内免费 | 10459篇 |
专业分类
耳鼻咽喉 | 2739篇 |
儿科学 | 8830篇 |
妇产科学 | 5615篇 |
基础医学 | 33704篇 |
口腔科学 | 4642篇 |
临床医学 | 33774篇 |
内科学 | 54190篇 |
皮肤病学 | 1967篇 |
神经病学 | 24212篇 |
特种医学 | 15215篇 |
外国民族医学 | 62篇 |
外科学 | 46781篇 |
综合类 | 32760篇 |
现状与发展 | 38篇 |
一般理论 | 23篇 |
预防医学 | 29914篇 |
眼科学 | 6857篇 |
药学 | 26872篇 |
119篇 | |
中国医学 | 10108篇 |
肿瘤学 | 28761篇 |
出版年
2024年 | 480篇 |
2023年 | 2182篇 |
2022年 | 5596篇 |
2021年 | 7213篇 |
2020年 | 5440篇 |
2019年 | 4741篇 |
2018年 | 26515篇 |
2017年 | 21763篇 |
2016年 | 23592篇 |
2015年 | 7866篇 |
2014年 | 9717篇 |
2013年 | 9517篇 |
2012年 | 19627篇 |
2011年 | 34576篇 |
2010年 | 28050篇 |
2009年 | 19229篇 |
2008年 | 28932篇 |
2007年 | 31323篇 |
2006年 | 9910篇 |
2005年 | 11217篇 |
2004年 | 10118篇 |
2003年 | 10962篇 |
2002年 | 8168篇 |
2001年 | 4824篇 |
2000年 | 4497篇 |
1999年 | 3687篇 |
1998年 | 2228篇 |
1997年 | 2122篇 |
1996年 | 1706篇 |
1995年 | 1517篇 |
1994年 | 1328篇 |
1993年 | 828篇 |
1992年 | 1143篇 |
1991年 | 996篇 |
1990年 | 898篇 |
1989年 | 737篇 |
1988年 | 689篇 |
1987年 | 609篇 |
1986年 | 469篇 |
1985年 | 374篇 |
1984年 | 237篇 |
1983年 | 183篇 |
1982年 | 120篇 |
1981年 | 104篇 |
1980年 | 122篇 |
1979年 | 121篇 |
1978年 | 62篇 |
1977年 | 59篇 |
1974年 | 64篇 |
1938年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
目的 探讨胰门板降低技术处理胰腺段胆总管巨大结石的应用价值。方法 回顾性分析上海交通大学医学院附属仁济医院近期收治的1 例利用胰门板降低技术取出胰腺段胆总管巨大结石的患者临床资料,并复习文献资料。结果 该例患者胰腺段胆总管内嵌顿一颗直径约2.5 cm质硬结石,纵行切开十二指肠上段胆总管前壁后采用液电碎石仪和取石钳难以碎石和取石,最终笔者首次利用胰门板降低技术显露胰腺段胆总管前壁后,继续纵行切开胰腺段胆总管才取出结石。术后经抗感染、补液等对症支持治疗痊愈出院,随访1 年半无结石复发和胆管狭窄。结论 胰门板降低技术可安全显露胰腺段胆总管,有助于取出胰腺段胆总管内嵌顿结石。 相似文献
13.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
14.
15.
16.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
17.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献18.
19.
Seyed Mehdi BagheriMofidi Majid Pouladian Seyed Behnamedin Jameie Ali Abbaspour Tehrani-Fard 《Australasian physical & engineering sciences in medicine / supported by the Australasian College of Physical Scientists in Medicine and the Australasian Association of Physical Sciences in Medicine》2016,39(3):717-726
Magnetic field generated by neuronal activity could alter magnetic resonance imaging (MRI) signals but detection of such signal is under debate. Previous researches proposed that magnitude signal change is below current detectable level, but phase signal change (PSC) may be measurable with current MRI systems. Optimal imaging parameters like echo time, voxel size and external field direction, could increase the probability of detection of this small signal change. We simulate a voxel of cortical column to determine effect of such parameters on PSC signal. We extended a laminar network model for somatosensory cortex to find neuronal current in each segment of pyramidal neurons (PN). 60,000 PNs of simulated network were positioned randomly in a voxel. Biot–savart law applied to calculate neuronal magnetic field and additional phase. The procedure repeated for eleven neuronal arrangements in the voxel. PSC signal variation with the echo time and voxel size was assessed. The simulated results show that PSC signal increases with echo time, especially 100/80 ms after stimulus for gradient echo/spin echo sequence. It can be up to 0.1 mrad for echo time = 175 ms and voxel size = 1.48 × 1.48 × 2.18 mm3. With echo time less than 25 ms after stimulus, it was just acquired effects of physiological noise on PSC signal. The absolute value of the signal increased with decrease of voxel size, but its components had complex variation. External field orthogonal to local surface of cortex maximizes the signal. Expected PSC signal for tactile detection in the somatosensory cortex increase with echo time and have no oscillation. 相似文献